High Intensity Strength Training & Bone Mineral Density in Young Women
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01482130|
Recruitment Status : Completed
First Posted : November 30, 2011
Last Update Posted : August 1, 2016
|Condition or disease||Intervention/treatment||Phase|
|Osteoporosis||Behavioral: Heavy, explosive strength training Behavioral: recommendations||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Preventing Osteoporosis: The Effect of High Intensity Strength Training on Bone Mineral Density in Young and Healthy Women|
|Study Start Date :||November 2011|
|Actual Primary Completion Date :||April 2012|
|Actual Study Completion Date :||June 2012|
Experimental: Training group
All participants in the training group will pursue a 12 weeks of strength training.
Behavioral: Heavy, explosive strength training
All participants of the training group will pursue a 12 weeks of heavy, explosive strength training, 3 sessions a week for a total of 36 sessions. The training session will include one squat exercise only, which allows muscle contraction of the quadriceps from a 90° bend at the knees to straight legs.
The control group will be encouraged to follow a training program according to recommended exercise guidelines
The control group will be encouraged to follow a training program according to recommended exercise guidelines:
- Bone mineral density [ Time Frame: Baseline and 12 weeks ](Dual X-ray Absorptiometry)
- Serum markers of bone metabolism [ Time Frame: Baseline and 12 weeks ]Blood samples will be drawn for analyses of bone metabolism and markers of bone formation; osteoprotegerin (OPG) and Type I procollagen N-terminal propeptide (PINP). Furthermore, Type 1 collagen C-breakdown products (CTX) and receptor activator of NF kappa B ligand (RANKL) which are the key regulators of bone resorption, will be analyzed at the start and end of the study.
- Body composition [ Time Frame: Baseline and 12 weeks ]Lean- versus fat mass, measured by Dual X-ray Absorptiometry (DXA).
- Maximal muscle strength [ Time Frame: Baseline and 12 weeks ]Measured as one repetition maximum in a squat exercise machine.
- Rate of force development [ Time Frame: Baseline and 12 weeks ]Maesured dynamic in a squat exercise maschine, and isometric at 90 degree angle in the knee joint.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01482130
|Norwegian University of Science and Technology|
|Trondheim, Sor.tronderlag, Norway, 7030|
|Study Director:||Unni Syversen, MD, PhD||Norwegian University of Science and Technology|